Nakamura Izumi, Kanazawa Masashi, Sato Yu, Irisawa Atsushi, Takagi Tadayuki, Ogata Takashi, Kashimura Shogo, Kenjo Akira, Suzuki Hiroyuki, Shibata Masahiko, Shimura Tatsuo, Ohira Hiromasa, Goto Mitsukazu, Takenoshita Seiichi, Ohto Hitoshi
Department of Organ Regulatory Surgery.
Fukushima J Med Sci. 2012;58(1):40-8. doi: 10.5387/fms.58.40.
Dendritic cells (DCs) are powerful antigen-presenting cells (APCs) that have attracted attention in recent years from the viewpoint of DC vaccine therapy against cancer. However, the existence of a strongly immunosuppressed state in cancer-bearing individuals inhibits DC maturation, which is one of the problems facing anti-cancer DC vaccine therapy. Isolated DCs loaded with tumor antigen ex vivo and administered as a cellular vaccine have been found to induce protective and therapeutic anti-tumor immunity in experimental animals. In clinical trials of DC vaccination for cancer patients, induction of anti-tumor immune responses and tumor regression has been observed. In this study, eighty-one advanced cancer patients unsuccessfully treated by established treatment in individual cases were selected between January 2002 and May 2007 at Fukushima Medical University. The usefulness of DC therapy was investigated by intradermal injection of peptide pulsed DCs for an overall objective response rate of 28.0%. Furthermore, direct injection of immature DCs into tumor extracted an overall objective response rate of 35.7%, and especially 40.0% for advanced pancreatic cancer by using endoscopic ultrasound-guided fine-needle injection technique as a novel approach. These results indicate that DC-based vaccination could be a promising treatment modality for various cancers, however multiple hurdles must be cleared before the development of an affordable DC-based vaccination can be used worldwide.
树突状细胞（DCs）是强大的抗原呈递细胞（APCs），近年来从DC疫苗治疗癌症的角度受到关注。然而，荷瘤个体中存在强烈的免疫抑制状态会抑制DC成熟，这是抗癌DC疫苗治疗面临的问题之一。已发现离体加载肿瘤抗原并作为细胞疫苗给药的分离DC可在实验动物中诱导保护性和治疗性抗肿瘤免疫。在癌症患者DC疫苗接种的临床试验中，已观察到抗肿瘤免疫反应的诱导和肿瘤消退。在本研究中，2002年1月至2007年5月期间，在福岛医科大学选择了81例经个体既定治疗未成功治疗的晚期癌症患者。通过皮内注射肽脉冲DC研究DC治疗的有效性，总体客观缓解率为28.0%。此外，通过将未成熟DC直接注射到肿瘤中，总体客观缓解率为35.7%，特别是对于晚期胰腺癌，通过使用内镜超声引导下细针注射技术作为一种新方法，缓解率为40.0%。这些结果表明，基于DC的疫苗接种可能是治疗各种癌症的一种有前景的治疗方式，然而，在开发出一种可在全球范围内使用的经济实惠的基于DC的疫苗接种之前，必须清除多个障碍。
